Price T Rowe Associates Inc Entrada Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,736,767 shares of TRDA stock, worth $16.8 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,736,767
Previous 2,903,025
5.73%
Holding current value
$16.8 Million
Previous $50.2 Million
50.71%
% of portfolio
0.0%
Previous 0.01%
Shares
14 transactions
Others Institutions Holding TRDA
# of Institutions
113Shares Held
28.7MCall Options Held
8.2KPut Options Held
2.3K-
Baker Bros. Advisors LP New York, NY4.87MShares$29.9 Million0.52% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$27.1 Million27.61% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$26.9 Million57.03% of portfolio
-
Janus Henderson Group PLC London, X02.12MShares$13 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$10.4 Million0.0% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $193M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...